National programme coordinators should re-visit guidelines, and investigate whether therapy changes in HIV co-infection should be universal, as recommended by the WHO [3], or in specific subgroups, such as those with low CD4 counts, to balance attempts to reduce morbidity and mortality in TB-HIV co-infection with awareness of resource constraints. Here, CD4 is linked to coinfection.